InvestorsHub Logo

RT Vegas

03/09/23 11:14 AM

#405366 RE: ggwpq #405364

You know, paying KM a $5 million performance bonus, you know, seems like shareholders, you know, are getting ripped-off, you know?

Whalatane

03/09/23 1:53 PM

#405392 RE: ggwpq #405364

gg. thx ...note some interesting detail on NVS's approach

Inclisiran was an NHS driven deal with Novartis, meaning they discounted the price so much to agree with NHS, that they're going to fund this for 300,000 patients. So theoretically, you can be listed on any formulary right away, because the government is saying I'm pushing for that.



So if I'm understanding this correctly .....NHS has said they we have identified the high risk group likely to benefit ...which is probably He Fh patients ( baseline LDL averaging in the low 300 mg/dl range ) ...and we will fund their coverage and list it on the formularies right away .

So then its up the the Cardiologists ( or NVS if they have access to these records ) to contact these patients and say ...its only 2 shots per yr ( after the first yr ) and we'll do it in our clinic .....and your LDL levels and risk of a CV event will be significantly reduced .

And the govt is paying for it ...so come in and sign up.. ( I'd sign up :--)

AMRN should be able to do the same thing with the recent 12 mth data following a CV event .....number needed to treat of 11 .
Identify all those with a recent CV event and follow NVS's approach.

Is it clear from KM's interview where we stand in the UK ?
Govt has agreed to reimburse ......but is that funded yet and on all formularies ?

Kiwi